1. China Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Shanghai RAAS Blood Products Co., Ltd. Class A

Shanghai RAAS Blood Products Co., Ltd. Class A

SSZSE:002252
4.77
CNY
-0.01
(-0.21%)
28.61BMarket Cap
Oct 28Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.28
0.32
0.41
0.48
0.39
0.37
0.51
0.44
0.63
0.98
1.21
1.23
1.12
- -
Basic EPS, GAAP
0.08
0.12
0.29
0.33
0.17
-0.31
0.12
0.21
0.19
0.28
0.27
0.33
0.24
- -
Free Cash Flow per Basic Share
-0.12
0.1
0.12
0.1
0.02
0.02
0.14
0.15
0.16
0.22
0.28
-0.13
-0.11
- -
Dividend per Share
0.01
0.02
0.03
0.04
0.04
0.03
- -
0.01
0.02
0.03
0.03
0.07
0.04
0.06
Book Value per Share
0.31
1.75
2.15
2.36
2.51
2.19
2.31
3.73
3.84
4.28
4.46
4.81
4.89
4.92
Tangible Book Value per Share
0.29
0.62
1.02
1.17
1.32
1.04
1.19
2.92
3.09
3.55
3.66
3.97
3.54
3.56
Basic Weighted Avg Shares
1,785
4,180
4,957
4,888
4,917
4,898
5,066
6,303
6,813
6,715
6,591
6,646
6,571
6,584
Sales/Revenue/Turnover
496
1,320
2,013
2,326
1,928
1,804
2,585
2,762
4,288
6,567
7,964
8,176
7,348
- -
Operating Margin (%)
37.71
44.01
42.55
47.97
43.45
30.92
36.01
38.84
34.58
30.92
29.47
26.8
22.84
- -
Depreciation Expense
17
60
103
112
143
150
148
153
159
185
163
207
233
- -
Net Income, GAAP
144
511
1,442
1,613
836
-1,518
608
1,324
1,295
1,880
1,779
2,193
1,577
- -
Effective Tax Rate (%)
15.66
15.19
15.37
15.77
17.2
- -
17.35
10.74
16.25
17.62
19.36
16.27
17.26
- -
Profit Margin (%)
28.97
38.71
71.64
69.35
43.36
-84.16
23.52
47.93
30.19
28.63
22.34
26.82
21.46
- -
Working Capital
806
2,342
4,560
5,201
6,275
3,488
4,222
4,682
5,566
6,849
6,431
7,606
7,215
8,242
LT Debt
357
358
360
360
- -
- -
- -
- -
4
2
1
13
2,484
2,573
Total Equity
1,102
8,624
10,712
11,730
12,480
10,900
11,491
25,130
25,904
28,813
29,650
31,941
32,456
32,414
Return on Invested Capital (%)
11.19
9.67
14.52
14.04
6.64
- -
5.42
7.34
5.11
6.86
6.13
7.3
4.65
- -
Return on Capital (%)
12.81
10.18
14.19
13.85
7.2
- -
5.42
7.26
5.09
6.9
6.09
7.12
4.72
- -
Return on Common Equity (%)
13.75
10.54
14.97
14.42
6.92
-13.01
5.44
7.23
5.07
6.87
6.09
7.13
4.9
- -

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,426
1,397
970
LT Borrowings
2,473
2,547
2,563
LT Finance Leases
10
10
9
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
6,638
6,638
6,593
Market Capitalization
42,085
38,633
28,612

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
9,951
10,403
10,602
Cash, Cash Equivalents & STI
1,401
1,882
1,556
Accounts Receivable, Net
1,842
1,906
2,043
Inventories
5,366
5,551
5,606
Total Current Liabilities
2,736
2,792
2,360
Payables & Accruals
- -
- -
- -
ST Debt
1,426
1,397
970
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.39%
5.31%
1.61%
Free Cash Flow
41.43%
-18.16%
-20.41%
Net Income, GAAP
-30.75%
6.57%
-28.1%
Sales/Revenue/Turnover
16.43%
24.45%
-10.13%
Total Cash Common Dividend
430.73%
48.82%
-41.21%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,056
2,196
2,062
1,862
8,176
2025
2,006
1,946
- -
1,257
7,348
2026
1,509
1,700
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.11
0.07
0.09
0.05
0.33
2025
0.08
0.07
- -
0.02
0.24
2026
0.05
0.05
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.03
0.03
- -
0.07
2025
- -
- -
- -
0.01
0.04
2026
0.02
0.03
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Jun Xu
Full Time Employees
4,045
Sector
Health technology
Industry
Biotechnology
Address
No. 2009, Wangyuan Road Shanghai SH China 201401
IPO Date
Jun 24, 2008
Website
raas-corp.com
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Shanghai RAAS Blood Products Co., Ltd. (002252.SZ) engages primarily in the research, development, production and sales of plasma-derived blood products in China. Founded in 1988 and headquartered at No. 2009 Wangyuan Road, Fengxian District, Shanghai, the company operates six production bases in Shanghai, Zhengzhou, Hefei, Wenzhou, Nanning and Hengyang, along with 55 plasma donation centers across 11 provinces including Guangxi, Hunan, Hainan, Shaanxi, Anhui, Guangdong, Inner Mongolia, Zhejiang, Hubei, Jiangxi and Shandong. Its core products encompass human albumin (Albumin RAAS), human immunoglobulin (pH4) for intravenous injection (γ-RAAS), human coagulation factor VIII (Human RAAS), human fibrinogen (Fibrinogen RAAS), prothrombin complex concentrate (human), freeze-dried (Prothrombin RAAS), thrombin (human) (Thrombin RAAS) and fibrin sealant (human) (Fibrin RAAS); specific immunoglobulins such as hepatitis B immunoglobulin, tetanus immunoglobulin and rabies immunoglobulin; and additional offerings including human intravenous immunoglobulin. The company extracts six key components from plasma, positioning it among China's leaders in plasma utilization rates, coagulation factor portfolios and export capabilities to regions like Southeast Asia and Latin America. Recent developments include Haier Group's 2024 acquisition of a 20% stake through Haiyingkang, integrating Shanghai RAAS into Haier's Incaier health ecosystem and establishing strategic partnerships with Grifols for bioscience and diagnostics; a 2025 acquisition of Nanyue Biopharmaceutical for at least 4.2 billion yuan to enhance supply chain and production efficiency; a March 2024 collaboration with Boehringer Ingelheim on hemophilia innovative drugs; and the advancement of SR604 injection into phase two clinical trials for hemophilia A/B and congenital factor VII deficiency. Shanghai RAAS maintains certifications as a Shanghai Foreign-Invested Advanced Technology Enterprise and High-Tech Enterprise, emphasizing quality under its "safety, quality, efficacy" policy while serving domestic healthcare markets and contributing to national strategic reserves.